Clinical Trial Update: Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone [Phase 2]

View source ↗

Summary

Phase II study evaluating carfilzomib, pomalidomide, and dexamethasone in multiple myeloma patients who relapsed after prior therapy; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib, pomalidomide, and dexamethasone

Snippet

Sponsor: Samsung Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN